# A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

> **NCT00835926** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 121 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza virus vaccine
- **BIOLOGICAL:** Influenza virus vaccine

## Key facts

- **NCT ID:** NCT00835926
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835926, "A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00835926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*